Toronto, Canada (PRWEB) August 25, 2014
Introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in 2011 and the resulting requirements for benefit assessment have fundamentally changed the conditions of market access and pharmaceutical pricing in Germany. The aim of this mandatory evaluation of clinical evidence was to limit the cost of pharmaceuticals and tackle the price monopoly of drug manufacturers in Germany.
While this has successfully been achieved, it has also brought with it further implications beyond the immediate German market, particularly for those countries that use Germany as a price reference. The open nature in which the clinical evidence and especially the critical aspects in these assessments is shared publically has potential impact on a product’s value story with payers in many other jurisdictions. For organizations working in this market or utilizing German price points for market access strategy, understanding these interconnections is critical.
Key take aways of this program include:
For more information or to register for this webinar, visit: AMNOG – German Regulation in the Past, Present and Future.
About Xcenda and Herescon
Xcenda is a strategic co
Copyright©2014 Vocus, Inc.
All rights reserved